1(S)-(6-methoxypyridin-3-yl)propylamine | 767351-03-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1(S)-(6-methoxypyridin-3-yl)propylamine
• 英文别名: (S)-1-(6-Methoxypyridin-3-yl)propan-1-amine；(1S)-1-(6-methoxypyridin-3-yl)propan-1-amine
• CAS: 767351-03-1
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: QHQMNKOGFJRYTE-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-(6-methoxypyridin-3-yl)propan-1-amine 生成 (R)-1-(6-methoxypyridin-3-yl)propylamine 、 1(S)-(6-methoxypyridin-3-yl)propylamine
  参考文献：
  名称：

  2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it

  摘要：

  该发明涉及化合物2-(丁基-1-磺酰氨基)-N-[1(R)-(6-甲氧基吡啶-3-基)丙基]苯甲酰胺（化学式I1）及其药用可接受的盐，它们的制备和用途，特别用于治疗和预防心房心律失常，例如心房颤动或心房扑动。

  公开号：

  US20040192738A1

文献信息

• SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：CZECHTIZKY Werngard

  公开号：US20130065859A1

  公开（公告）日：2013-03-14

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色甘醇-6-氧基)-噻唑衍生物，其中Ar、R2、R3和R4如权利要求中所定义。式I的化合物是钠-钙交换蛋白（NCX）的抑制剂，特别是亚型1的钠-钙交换蛋白（NCX1），适用于处理细胞内钙离子稳态受扰的各种疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• Optically Active Amines by Enzyme-Catalyzed Kinetic Resolution
  作者：Klaus Ditrich

  DOI：10.1055/s-2008-1078451

  日期：2008.7

  Chiral amines are resolved by an enzyme-catalyzed kinetic resolution. Key steps are the selective acylation of one enantiomer with isopropyl methoxyacetate, separation of the resulting amide from the unreacted antipode, and finally amide hydrolysis. The process proceeds with excellent selectivity and is highly flexible with regard to substrates.

  手性胺通过酶催化动力学拆分进行拆分。关键步骤是用甲氧基乙酸异丙酯选择性酰化一种对映体，将所得酰胺与未反应的对映体分离，最后是酰胺水解。该过程以优异的选择性进行，并且对于基材具有高度的灵活性。
• SULFONYLAMINOBENZOIC ACID AND SALT
  申请人：Brendel Joachim

  公开号：US20080081926A1

  公开（公告）日：2008-04-03

  The invention relates to a compound selected from the group consisting of which is suitable for use in the synthesis of 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide.

  本发明涉及一种化合物，选自以下组合物，适用于2-(丁基-1-磺酰氨基)-N-[1(R)-(6-甲氧基吡啶-3-基)丙基]苯甲酰胺的合成。
• SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi

  公开号：US20140243292A1

  公开（公告）日：2014-08-28

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色烯-6-氧基)-噻唑，其中Ar，R2，R3和R4如权利要求所定义。公式I化合物是钠钙交换器（NCX）的抑制剂，特别是钠钙交换器亚型1（NCX1）的抑制剂，并适用于治疗细胞内钙离子稳态受到干扰的多种疾病，如心律失常，心力衰竭和中风。本发明还涉及制备公式I化合物的方法，它们作为药物的用途，以及包含它们的制药组合物。
• 2-(Butyl-1-sulfonylamino)-n-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
  申请人：BRENDEL Joachim

  公开号：US20090209767A1

  公开（公告）日：2009-08-20

  The invention relates to 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)propyl]benzamide of the formula I and to its pharmaceutically acceptable salts, their preparation and use, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation or atrial flutters.

  该发明涉及公式I的2-(丁基-1-磺酰氨基)-N-[1(R)-(6-甲氧基-吡啶-3-基)丙基]苯甲酰胺及其药学上可接受的盐，它们的制备和用途，特别是用于治疗和预防心房心律失常，例如心房颤动或心房扑动。